Company Overview of Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing novel topical dermatological therapeutics. The company develops A-101, a topical therapy for the treatment of seborrheic keratosis (a skin tumor in man). It is also engaged in pursuing additional dermatological indications for its product, as well as evaluating other dermatologic assets in various stages of preclinical and clinical development; and the development of topical agents for the treatment and prevention of various medical and cosmetic indications. Aclaris Therapeutics, Inc. was founded in 2012 and is based in Malvern, Pennsylvania.
101 Lindenwood Drive
Malvern, PA 19355
Founded in 2012
Key Executives for Aclaris Therapeutics, Inc.
Chief Executive Officer, President and Director
Vice President of Clinical Operations
Compensation as of Fiscal Year 2015.
Aclaris Therapeutics, Inc. Key Developments
Aclaris Therapeutics, Inc. Announces Statistically Significant Results from Phase 2 Clinical Trial of Its Lead Drug Candidate, A-101
Mar 17 15
Aclaris Therapeutics, Inc. announced statistically significant results from a Phase 2 clinical trial of its lead drug candidate, A-101. In the trial, A-101 demonstrated clinically and statistically significant improvements in removing seborrheic keratosis (SK) lesions on the face. SK is one of the most common types of skin tumors. Although the lesions are benign, many patients elect to have SK treated, either because the lesions have become irritated or because the patient feels they are cosmetically concerning. The double-blind, vehicle-controlled Phase 2 clinical trial was designed to evaluate the safety, tolerability and effectiveness of A-101 in removing targeted SK lesions on the face. The trial used a parallel-group design to compare two concentrations of A-101 and vehicle (placebo) in 120 subjects with SK lesions on the face. Results from the trial showed A-101 achieved statistical significance in clearing SK lesions in a dose-related fashion. A-101 was well tolerated at both concentrations studied. SK are among the most common skin tumors seen in middle-aged and older adults, affecting over 83 million people in the United States.i SK lesions have a waxy, scaly, slightly elevated appearance and often multiple growths are present. Currently, SK lesions are treated using modalities such as cryosurgery, electrosurgery, curettage, or surgical removal which may be painful and may often result in pigmentary changes and/or scarring at the treatment site.
Aclaris Therapeutics, Inc. Presents at Leerink's Global Healthcare Conference, Feb-12-2015 01:00 PM
Jan 30 15
Aclaris Therapeutics, Inc. Presents at Leerink's Global Healthcare Conference, Feb-12-2015 01:00 PM. Venue: Waldorf Astoria New York, New York, New York, United States. Speakers: Neal Walker, Chief Executive Officer, President and Director.
Aclaris Therapeutics Announces Positive Results from Phase 2B Clinical Trial of A-101 for the Removal of Seborrheic Keratosis
Jan 27 15
Aclaris Therapeutics, Inc. announced positive results from a Phase 2b clinical trial of the Company's lead drug, A-101. In the trial, A-101 demonstrated clinically and statistically significant improvements in clearing multiple seborrheic keratoses (SK), one of the most common types of skin tumors. Though the lesions are benign, many patients elect to have SK treated, either because the lesions are irritated or are cosmetically concerning. The double-blind, vehicle-controlled Phase 2b clinical trial was designed to evaluate the safety, tolerability and efficacy of A-101 in removing multiple SK lesions on the trunk and extremities. The trial used a parallel-group design to compare two concentrations of A-101 and vehicle (placebo) in 172 subjects with SK lesions. Results from the study showed A-101 achieved statistical significance in clearing SK lesions in a dose-related fashion. A-101 was well tolerated at both concentrations studied. This positive outcome represents an important milestone for A-101 and further demonstrates its potential as a non-invasive treatment for SK, a condition for which there are currently no FDA-approved therapies. These study results are promising and suggest that A-101 may have the potential to address an unmet medical need and an investigator on multiple A-101 clinical trials. While cryotherapy is the most commonly used treatment for the removal of SK lesions, it is painful for patients and sometimes results in permanent hypopigmentation. A well-tolerated, FDA-approved, non-invasive treatment option for SK would be a welcome advance for patients and physicians.
Similar Private Companies By Industry
Recent Private Companies Transactions
September 30, 2014